Tumor organoids: feasibility to predict sensitivity to treatment in cancer patients (TUMOROID trial)

Tumor organoids: feasibility to predict sensitivity to treatment in cancer patients (TUMOROID trial) - TUMOROID

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44690

Enrollment

665

Registered

2014-07-09

Start date

2014-10-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast) colorectal disseminated cancer (lung Metastatic cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients with locally advanced (incurable) or metastatic colorectal, breast or lung (non-small cell) cancer who will start treatment with one of the regimens specified in the protocol. - Measurable/evaluable disease - Safe histologic tumor biopsy possible - WHO 0-2

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
• Area under the (partial) receiver operating characteristics (ROC) curve • Optimal organoid screening test threshold and associated accuracy measures (sensitivity, specificity, positive predictive value, negative predictive value)	—

Secondary

Measure	Time frame
• Success rate of organoid culture from biopsies of colorectal, breast and lung cancer	—

Countries

Netherlands

Outcome results